Literature DB >> 29344222

Herbal compound Teng-Long-Bu-Zhong-Tang inhibits metastasis in human RKO colon carcinoma.

Meng-Meng Wei1,2,3, Shuang-Shuang Wang1,2, Jia-Lu Zheng1,2, Jin-Jun Chen4, Xia Yan1,2, Hong-Mei An5, Bing Hu1,2.   

Abstract

Metastasis is one of the primary obstacles to the successful treatment of colorectal cancer. Teng-Long-Bu-Zhong-Tang (TLBZT) is a modern Chinese herbal formula that may be useful in the treatment of metastatic colorectal cancer. The present study evaluated the effects of TLBZT on lung metastasis in human RKO colon carcinoma cells injected into mice via the tail vein. The results demonstrated that TLBZT inhibited the metastasis of human RKO colon carcinoma cells to the lungs. TLBZT downregulated the expression of LOX and hypoxia-inducible factor 1α. TLBZT also inhibited the expression of integrins αV and β3 and the phosphorylation of focal adhesion kinase. These results indicate that TLBZT inhibits the lung metastasis of RKO colon carcinoma by regulating the expression of multiple genes. The results of the present study provide a new basis for the management of colorectal cancer metastasis using treatments derived from Chinese herbs.

Entities:  

Keywords:  colorectal carcinoma; focal adhesion kinase; hypoxia-inducible factor 1α; integrins αV and β3; lysyl oxidase; metastasis

Year:  2017        PMID: 29344222      PMCID: PMC5755261          DOI: 10.3892/ol.2017.7206

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


Introduction

Colorectal carcinoma is the third most common cancer in males and the second most common in females (1). Metastasis is the primary cause of treatment failure in patients with colorectal cancer and usually occurs in the liver, lungs and other organs due to the malignant characteristics of the disease (2,3). Current treatments of metastatic colorectal cancer include surgery, chemotherapy and targeted therapy, which uses small molecule-based drugs or monoclonal antibodies against abnormally expressed proteins that are essential for cancer cell growth, including anti-EGFR agents, e.g., cetuximab and panitumumab, in addition to anti-VEGF agents, e.g., bevacizumab and aflibercept (4). Due to unresectable metastatic lesions, only a small proportion of patients with metastatic colorectal cancer are eligible to undergo surgery (5,6). Furthermore, chemotherapy induces toxic side effects and targeted therapy is very expensive, meaning that few patients with metastatic colorectal cancer receive suitable treatment. Currently, the 5-year survival rate of patients with metastatic colorectal cancer is <15% (7,8). Therefore, it is necessary to develop a novel approach to treat and prevent metastasis in colorectal cancer. Traditional Chinese medicine (TCM) may be used as a method of treating colorectal cancer. Syndrome differentiation-based treatment with TCM decoctions can alleviate symptoms, improve quality of life and immune function, produce synergistic effects alongside anti-cancer chemotherapy, prevent cancer recurrence and metastasis and prolong the survival time of patients with colorectal cancer (9,10). Based on the principles and practice of TCM, the formula, Teng-Long-Bu-Zhong-Tang (TLBZT) has been produced that may potentially be used to treat patients with colorectal cancer. Previous studies have suggested that TLBZT inhibits proliferation and induces apoptosis and senescence in colon cancer cells (11–13). Some of the herbs present in TLBZT have been studied. Actinidia chinensis and Duchesnea indica can inhibit cell proliferation in suspension, induce active oxygen production, activate caspase-3 and induce anoikis in colorectal cancer cells (14,15). Anoikis is a form of programmed cell death elicited when cells detach from the extracellular matrix (ECM) and is closely associated with the survival of tumor cells in a liquid environment, including the blood and lymph circulation. Therefore, inhibiting the growth of tumor cells in suspension and inducing anoikis may suppress cancer metastasis. Furthermore, Solanum nigrum, one of the herbs present in TLBZT, inhibits the proliferation, adhesion, migration and invasion of colorectal cancer cells (16). These observations suggest that TLBZT may inhibit the metastasis of colorectal cancer cells. The present study evaluated the effect of TLBZT on colorectal cancer metastasis in vivo. The effects of TLBZT on the expression of the metastasis-associated genes, including lysyl oxidase (LOX), hypoxia-inducible factor 1α (HIF-1α), integrins αv and β3 and the phosphorylation of focal adhesion kinase (p-FAK), were also determined. The results demonstrated that TLBZT inhibits the metastasis of human RKO colon carcinoma cells to the lungs, downregulates the expression of LOX, HIF-1α, integrin αV and β3, and inhibits FAK phosphorylation.

Materials and methods

Reagents

Dulbecco's Modified Eagle's medium (DMEM) and fetal bovine serum were obtained from Hyclone; GE Healthcare Life Sciences (Logan, UT, USA). The antibody against LOX was purchased from Novus Biologicals (Littleton, CO, USA) (cat. no. NB100-2527). The antibody against HIF-1α was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) (cat. no. sc-53546). Antibodies against integrins αV (cat. no. BS3513) and β3 (cat. no. BS1187), phosphorylated (p)-FAK (cat. no. BS4617), horseradish peroxidase (HRP)-conjugated-anti-rabbit IgG (cat. no. BS13278) and anti-Mouse IgG-HRP (cat. no. BS12478) were procured from Bioworld Technology, Inc. (St. Louis Park, MN, USA).

TLBZT extraction

The major herbs in the TLBZT formula (Chinese patent ZL200910197565.2) are: The roots of A. chinensis (30 g), S. nigrum (15 g), D. indica (15 g), Atractylodes macrocephala (9 g), Coix seed (30 g) and Viscum coloratum (15 g). All the aforementioned herbs were obtained from Longhua Hospital (Shanghai, China) in accordance with the amounts required for the TLBZT formula and decocted twice with 8-fold distilled water at 100°C for 1 h. The decoctions were merged, filtered and made up to a concentration of 1.5 g crude herb materials/ml water and stored at 4°C.

RKO cell culture

Human colon carcinoma RKO cells were obtained from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Beijing, China). RKO cells were cultured in DMEM with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 µg/ml) and maintained at 37°C with 5% CO2 in a humidified atmosphere for 2-3 days until cells reached 80% confluence. Cells were subsequently passaged to new plates.

Animal model

A total of 30 male 6–7-week old BALB/c nude mice were purchased from the Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). Mice were acclimatized for 1 week in pathogen-free conditions at the animal laboratory of Longhua Hospital with a 12 h light/dark cycle, regulated temperature of 24±2°C and humidity of 50±10%, with ad libitum access to water and animal chow. Mice were injected with 2×106 RKO cells in 0.1 ml PBS through the tail vein. Subsequently, mice were randomly divided into 3 groups (n=10 mice/group), and intragastrically administrated with either 11.25 g/kg/0.3 ml TLBZT, 22.5 g/kg/0.3 ml TLBZT or same volume of distilled water, once a day. Following 2 months treatment, mice were sacrificed by cervical dislocation, mouse lungs were removed and weighed, and metastatic nodules on the lung surface were counted. The Longhua Hospital Animal Care and Use Committee approved all studies involving mice.

Histochemistry

Lung tissues were fixed in 4% paraformaldehyde in PBS at 4°C overnight, embedded in paraffin and cut into 4 µm thick sections. Sections were then deparaffinized with xylene two times for 10 min, re-hydrated with 100, 95 and 70% alcohol for 2 min, and stained with hematoxylin and eosin for 4 min and 1 min respectively, and mounted with xylene based mounting medium. Slides were visualized using an Olympus light microscope (Olympus Corporation, Tokyo, Japan).

Immunohistochemistry (IHC)

Lung tissues were fixed, embedded and cut as described above. For IHC, sections were blocked with 3% hydrogen peroxide for 15 min at room temperature, blocked with 5% normal goat serum (Cell Signaling Technology, Inc., Danvers, MA, USA) for 30 min at 37°C, and subsequently incubated with primary antibodies against LOX (1:100), integrin αV (1:100), integrin β3 (1:100), p-FAK (1:100) and HIF-1α (1:200) at 4°C overnight. Sections were then incubated with the appropriate HRP-conjugated anti-rabbit/anti mouse IgG secondary antibody (1:4,000) at 37°C for 30 min and visualized using 3,3-diaminobenzidine at room temperature for 3–5 min. Sections were then counterstained with hematoxylin for 45 sec at room temperature and mounted with glass coverslips. Slides were observed using an Olympus light microscope (Olympus Corporation). Five fields at ×200 magnification were randomly selected from each slide and analyzed using Image-Pro Plus 6.0 software (Media Cybernetics, Rockville, MD, USA).

Statistical analyses

Data are expressed as the mean ± standard deviation. Differences among groups were analyzed using one-way analysis of variance followed by a least significant difference (LSD) test. P≤0.05 was considered to indicate a statistically significant difference.

Results

TLBZT inhibits the lung metastasis of colorectal cancer cells

Following treatment with TLBZT, lungs from nude mice were removed and weighed, and the number of metastatic nodules on the lung surface was counted. The results demonstrated that the number of metastatic nodules on the lung surface decreased following treatment with TLBZT in a dose-dependent manner (Fig. 1A; P<0.05). Furthermore, lung weight was significantly reduced in a dose-dependent manner following treatment with TLBZT (Fig. 1B; P<0.05). Pathology indicates that TLBZT markedly inhibited the growth of metastatic nodules in the lung (Fig. 1C). Following treatment with TLBZT, no significant adverse consequences were observed, including weight loss (Fig. 1D), ruffling of fur, changes in behavior and feeding (data not shown). These results suggest that TLBZT inhibits the metastasis of colorectal carcinoma without inducing toxicity.
Figure 1.

Effect of TLBZT on the metastasis of colorectal cancer to the lungs. Male BALB/c nude mice were injected 2×106 RKO cells through the tail vein and received intragastric administration of 11.25 g/kg/0.3 ml or 22.5 g/kg/0.3 ml TLBZT, or the same volume of distilled water once a day. Following 2 months treatment, mouse lungs were removed. (A) The number of metastatic nodules on the lung surface were counted. (B) Lung weights were measured (C) Hematoxylin and eosin staining indicating metastasis in the lung at ×200 magnification. (D) The body weights of the mice in each group were compared prior to and following treatment. *P<0.05 and **P<0.01 vs. control group. TLBZT, Teng-Long-Bu-Zhong-Tang.

TLBZT inhibits the expression of LOX

LOX is associated with the remodeling of the ECM, which serves an important role in tumor metastasis and may be a target for regulating cancer metastasis (17,18). The present study demonstrated that LOX was overexpressed in lung metastases from RKO colorectal cancer and that treatment with TLBZT significantly inhibited its expression (Fig. 2; P<0.01).
Figure 2.

The effect of TLBZT on LOX expression. (A) The expression of LOX in lung metastatic lesions was detected by immunohistochemistry and observed using a microscope at ×200 magnification. (B) The mean optical density of LOX was determined using Image-Pro Plus 6.0 software and expressed as a fold of the control **P<0.01 vs. control. TLBZT, Teng-Long-Bu-Zhong-Tang; LOX, lysyl oxidase.

TLBZT inhibits the expression of HIF-1α

It has been demonstrated that the expression of LOX is regulated by HIF-1α (19); therefore, the current study determined the effect of TLBZT treatment on HIF-1α expression. The results demonstrated that HIF-1α was highly expressed in lung metastases from RKO colorectal carcinoma, but that TLBZT significantly inhibited its expression (Fig. 3; P<0.01).
Figure 3.

Effects of TLBZT on HIF-1α expression. (A) The expression of HIF-1α in lung metastatic lesions was detected by immunohistochemistry and observed using a microscope at ×200 magnification. (B) The mean optical density of HIF-1α was determined using Image-Pro Plus 6.0 software and expressed as a fold of the control **P<0.01 vs. control. TLBZT, Teng-Long-Bu-Zhong-Tang; HIF-1α, hypoxia-inducible factor 1α.

TLBZT inhibits the expression of integrins αV and β3

Integrins serve an important role in cell-cell and cell-ECM interactions and participate in the process of tumor metastasis; thus, their inhibition may suppress cancer metastasis (20–22). Therefore, the effects of TLBZT treatment on integrin expression were assessed. Integrins αV and β3 were overexpressed in lung metastases from RKO colorectal cancer; however, treatment with TLBZT significantly inhibited their expression (Fig. 4; all P<0.01).
Figure 4.

Effects of TLBZT on the expression of integrins. (A) The expression of integrins αV and β3 in lung metastatic lesions were detected by immunohistochemistry and observed using a microscope at ×200 magnification. (B) The mean optical density of integrins αV and β3 was analyzed using Image-Pro Plus 6.0 software and expressed as a fold of the control. **P<0.01 vs. control. TLBZT, Teng-Long-Bu-Zhong-Tang.

TLBZT inhibits FAK phosphorylation

The transduction of the downstream signals of integrins are associated with the phosphorylation of FAK (23), therefore the effects of TLBZT on FAK phosphorylation were assessed using immunohistochemistry. FAK was highly phosphorylated in lung metastases from RKO colorectal cancer. However, treatment with TLBZT significantly inhibited the phosphorylation of FAK (Fig. 5; P<0.01).
Figure 5.

Effects of TLBZT on FAK phosphorylation. (A) The phosphorylation of FAK in lung metastatic lesions was detected by immunohistochemistry and observed using a microscope at ×200 magnification. (B) The mean optical density of FAK phosphorylation was determined with Image-Pro Plus 6.0 software and expressed as a fold of the control. **P<0.01 vs. control. TLBZT, Teng-Long-Bu-Zhong-Tang; FAK, focal adhesion kinase.

Discussion

According to TCM, the basic pathogenesis of colorectal cancer is associated with toxicity, dampness and spleen-deficiency, and the therapeutic principles of TLBZT are considered to be detoxification, overcoming dampness and tonifying the spleen (9,10). Furthermore, all the herbs contained in the TLBZT formula exhibit anti-cancer effects and are commonly used in clinical oncology. A. chinensis inhibits colorectal cancer cell proliferation and induces apoptosis via mitochondrial pathways (24). S. nigrum inhibits cell proliferation, induces autophagy and enhances the cytotoxic effect of chemotherapeutic drugs in colorectal cancer cells (25). D. indica inhibits cell proliferation, promotes cell apoptosis and arrests the cell cycle in the S-phase in cervical cancer (26). Atractylenolide I, a component of A. macrocephala, is able to inhibit cell survival and induce apoptosis by upregulating the expression of caspase-2, caspase-9 and Bax, and downregulating the expression of Bcl-2 and Bcl-XL (27). Kanglaite, a Chinese herb product extracted from the Coix seed, induces apoptosis in cancer cells and is widely used to treat different types of cancer, including lung, liver and gastric cancer (28–30). V. coloratum inhibits cell proliferation and promotes the apoptosis of colorectal cancer cells via inhibition of nuclear factor-κB (31). These results suggest that TLBZT is a herbal formula that exhibits anti-cancerous effects according to TCM theories and clinical practice. LOX, a type of ECM-modifying enzyme, is involved in the remodeling of ECM. It is highly expressed in colorectal cancer and is considered to promote tumor metastasis (17,18,32,33). Inhibiting LOX expression impairs tumor cell metastasis, therefore LOX has become a target for cancer treatment (34,35). The expression of LOX is regulated by HIF-1α, which is degraded by ubiquitination in normoxic conditions. However, HIF-1α degradation is inhibited in hypoxic conditions and it forms heterodimers with HIF-1β, which activates the expression of downstream genes, including vascular endothelial growth factor and LOX, which are involved in angiogenesis and metastasis (36). The results of the present study demonstrated that LOX and HIF-1α are overexpressed in metastatic lesions in the lung that arise from colorectal cancer cells. Treatment with TLBZT significantly inhibited LOX and HIF-1α expression, suggesting that inhibition of LOX and HIF-1α contributes to the TLBZT-mediated prevention of colorectal cancer metastasis. Integrins, consisting of α and β subtypes, are transmembrane proteins that mediate cell-cell and cell-ECM interactions (37,38). The extracellular domains of integrins α and β form a ligand binding domain for binding ligands, including fibrinogen, fibronectin and intercellular adhesion molecules (37,38). The downstream signal transduction of integrins is associated with the FAK signaling pathway and they are able to mediate the biological behavior of cells, including cell migration, invasion and metastasis (23,39). Integrin αVβ3 is a heterodimer formed by the non-covalent linking of the integrin αV and β3 subunits. It is widely expressed in tumor tissues and is closely associated with tumor metastasis (39,40). Antagonizing integrin αVβ3 or inhibiting its ligand, osteopontin may effectively inhibit colorectal cancer metastasis (22,41). The results of the present study indicate that integrin αVβ3 is overexpressed and that FAK is highly phosphorylated in metastatic cells of RKO colorectal carcinoma. TLBZT may inhibit the expression of integrin αVβ3 and the phosphorylation of FAK. These results suggest that inhibiting integrin αVβ3-FAK signal transduction may induce the anti-metastatic effects observed following treatment with TLBZT in colorectal cancer. To conclude, the present study demonstrated that TLBZT inhibits the metastasis of RKO colorectal cancer cells and that this may be associated with the inhibition of HIF1α-LOX and integrin αVβ3-FAK signal transduction. These results provide a novel insight for the treatment and prevention of colorectal cancer metastasis with TLBZT.
  35 in total

Review 1.  Treatment of metastatic colorectal cancer.

Authors:  Janine M Davies; Richard M Goldberg
Journal:  Semin Oncol       Date:  2011-08       Impact factor: 4.929

2.  Kanglaite injection combined with hepatic arterial intervention for unresectable hepatocellular carcinoma: a meta-analysis.

Authors:  Fei Fu; Yeda Wan; Tao Wu
Journal:  J Cancer Res Ther       Date:  2014-08       Impact factor: 1.805

Review 3.  Integrin-regulated FAK-Src signaling in normal and cancer cells.

Authors:  Satyajit K Mitra; David D Schlaepfer
Journal:  Curr Opin Cell Biol       Date:  2006-08-17       Impact factor: 8.382

4.  [Effects of Tenglong Buzhong Decoction on proliferation and apoptosis of human colon carcinoma cell line LS174T].

Authors:  Bing Hu; Hong-Mei An; Ke-Ping Shen; Qin DU
Journal:  Zhong Xi Yi Jie He Xue Bao       Date:  2010-06

5.  Lysyl oxidase, extracellular matrix remodeling and cancer metastasis.

Authors:  Qian Xiao; Gaoxiang Ge
Journal:  Cancer Microenviron       Date:  2012-04-13

Review 6.  Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis.

Authors:  Thomas R Cox; Alison Gartland; Janine T Erler
Journal:  Cancer Res       Date:  2016-01-05       Impact factor: 12.701

Review 7.  Integrin-based therapeutics: biological basis, clinical use and new drugs.

Authors:  Klaus Ley; Jesus Rivera-Nieves; William J Sandborn; Sanford Shattil
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

8.  Anti-tumor effects of atractylenolide I isolated from Atractylodes macrocephala in human lung carcinoma cell lines.

Authors:  Huanyi Liu; Yajie Zhu; Tao Zhang; Zhenguo Zhao; Yu Zhao; Peng Cheng; Hua Li; Hui Gao; Xiaomei Su
Journal:  Molecules       Date:  2013-10-29       Impact factor: 4.411

9.  Teng-Long-Bu-Zhong-Tang, a Chinese herbal formula, enhances anticancer effects of 5--Fluorouracil in CT26 colon carcinoma.

Authors:  Shan Deng; Bing Hu; Hong-Mei An; Qin Du; Ling Xu; Ke-Ping Shen; Xiu-Feng Shi; Meng-Meng Wei; Yang Wu
Journal:  BMC Complement Altern Med       Date:  2013-06-08       Impact factor: 3.659

Review 10.  Role of targeted therapy in metastatic colorectal cancer.

Authors:  Yoshihito Ohhara; Naoki Fukuda; Satoshi Takeuchi; Rio Honma; Yasushi Shimizu; Ichiro Kinoshita; Hirotoshi Dosaka-Akita
Journal:  World J Gastrointest Oncol       Date:  2016-09-15
View more
  2 in total

1.  Fibrostenotic eosinophilic esophagitis might reflect epithelial lysyl oxidase induction by fibroblast-derived TNF-α.

Authors:  Yuta Kasagi; Kara Dods; Joshua X Wang; Prasanna M Chandramouleeswaran; Alain J Benitez; Fiona Gambanga; Jonathan Kluger; Tokunbo Ashorobi; Jonathan Gross; John W Tobias; Andres J Klein-Szanto; Jonathan M Spergel; Antonella Cianferoni; Gary W Falk; Kelly A Whelan; Hiroshi Nakagawa; Amanda B Muir
Journal:  J Allergy Clin Immunol       Date:  2018-12-20       Impact factor: 14.290

Review 2.  Recent Advances in Anti-Metastatic Approaches of Herbal Medicines in 5 Major Cancers: From Traditional Medicine to Modern Drug Discovery.

Authors:  Jinkyung Park; Dahee Jeong; Meeryoung Song; Bonglee Kim
Journal:  Antioxidants (Basel)       Date:  2021-03-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.